Market Place
Sourcing Support
Orasis Pharmaceuticals Licenses Qlosi™ Ophthalmic Solution In Korea
16 Oct 2024 //
PR NEWSWIRE
TB, Asthma, Glaucoma, Bipolar Meds To Rise By 50% Cost by NPPA
15 Oct 2024 //
FINANCIALXPRESS
Orasis Pharmaceuticals Strengthens Leadership Team For Qlosi
14 Oct 2024 //
PR NEWSWIRE
Orasis Pharma Completes $78 Million Financing to Launch Qlosia
08 Oct 2024 //
PR NEWSWIRE
Orasis gains FDA approval for presbyopia eye drops
19 Oct 2023 //
PR NEWSWIRE
AbbVie culls a second-gen presbyopia eye drop
27 Jun 2023 //
ENDPTS
Enforcement Report - Week of June 7, 2023
07 Jun 2023 //
FDA
Arctic Vision Begins Enrollment in PIII Trial of ARVN003 for Presbyopia
04 Jul 2022 //
ASIAONE
Allergan Shows Positive Topline Phase 3 Results of VUITY 1.25% in Presbyopia
05 Apr 2022 //
PRNEWSWIRE
VUITY 1.25% for Age-Related Blurry Near Vision (Presbyopia), is Now Available
09 Dec 2021 //
PRNEWSWIRE
FDA clears AbbVie’s Vuity as first eye drop for presbyopia
03 Nov 2021 //
FIERCEPHARMA
AbbVie lands FDA approval for Allergan`s blurred-vision eye drop
01 Nov 2021 //
ENDPTS
U.S. Food and Drug Administration Approves VUITY™
29 Oct 2021 //
PRNEWSWIRE
NMPA clears Arctic Vision’s IND for phase III study of ARVN003 in presbyopia
04 Sep 2021 //
PHARMABIZ
Allergan’s ophthalmic solution shows near vision gains in presbyopia trials
30 Oct 2020 //
CLINICALTRIALSARENA
Amneal`s Generic Pilocarpine Hydrochloride Receives Approval In US
21 Sep 2020 //
FDA
Aurobindo Pharma`s Generic Pilocarpine Hydrochloride Receives Approval in US
16 Aug 2019 //
FDA
ADVANZ PHARMA Corp. Acquires International Rights to Two Medicines
01 Apr 2019 //
PR NEWSWIRE
Dermavant hires CSO from GSK, buys excessive sweating drug
04 Apr 2018 //
FIERCE BIOTECH
Akorn’s Generic Pilocarpine Hydrochloride Receives Approval In US
30 Sep 2017 //
FDA
Enforcement Report - Week of May 3, 2017
03 May 2017 //
FDA
Ganaxolone & Diazepam Administered I.V. Block Seizures in Animal Model
15 Nov 2016 //
GLOBENEWSWIRE
Firms Team Up To Sustain Natural Pilocarpine
17 Mar 2015 //
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.